ACNR
Journal for advances in Clinical Neuroscience and Rehabilitation
- Website
- acnr.co.uk · all feeds from this site
- Feed URL
https://acnr.co.uk/feed/
Read it in your FeedListing reader
Or add to: Feedly Inoreader Raw feed
Latest posts
-
FDA approves first gene therapy for children with Sanfilippo syndrome type A
The US Food and Drug Administration (FDA) has approved Fayuvi (rebisufligene etisparvovec-hopf), the first approved treatment for children with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A. The gene therapy offers a new treatment option…
-
Blood proteins may help monitor the effects of Alzheimer’s drug
Researchers have identified changes in dozens of blood proteins in people receiving lecanemab, an anti-amyloid treatment for Alzheimer’s disease. The findings suggest that blood-based biomarkers could eventually help clinicians assess treatment responses, track changes…
-
FDA approves levacetylleucine for ataxia-telangiectasia
The US Food and Drug Administration (FDA) has approved levacetylleucine (Aqneursa, IntraBio) for the treatment of ataxia in adults and children with ataxia-telangiectasia (A-T) weighing at least 15 kg. The decision marks the first FDA-approved treatment specifically indicated…
-
Common herpes viruses have differing associations with multiple sclerosis risk
A large study involving more than 320,000 people in Israel has identified differing associations between common herpesvirus infections and the risk of developing multiple sclerosis (MS). Published in Brain, Behavior, and Immunity, the research confirmed the established link…
-
Early MS treatments differ most in relapses and MRI lesions, not disability
Early treatment choices for multiple sclerosis (MS) are associated with differences in relapse rates and brain lesion measurements, but not disability outcomes after two years, according to a study published on 9 September 2026 in Neurology Open Access. The research, involving…
-
Greater physical activity associated with slower progression of Parkinson’s disease
Higher levels of physical activity are associated with slower declines in cognitive function and less worsening of movement symptoms in people with Parkinson’s disease, according to research published on 7 October 2026 in Neurology, the medical journal of the American Academy of…
-
Migraine and endometriosis overlap may be substantially under-recorded, large analysis suggests
Migraine and endometriosis may coexist considerably more frequently than routine healthcare records suggest, according to a meta-analysis involving more than 13 million women. The findings, presented at the 2026 American Neurological Association Annual Meeting, highlight the…
-
N-CODE launches funding challenge to drive innovation in neurological care
Researchers, businesses and technology developers are being invited to apply for funding to develop innovative approaches to neurological healthcare through a new initiative led by the University of Plymouth. The N-CODE Innovation Challenge will award up to £12,000 to…
-
FDA approves ISEMBYLD as muscle-targeted treatment for spinal muscular atrophy
The US Food and Drug Administration (FDA) has approved ISEMBYLD (apitegromab-mstn) for adults and children aged two years and older with spinal muscular atrophy (SMA) who are receiving a survival motor neuron 2 (SMN2)-targeted treatment. Developed by Scholar Rock, ISEMBYLD is…
-
MODAG wins CPHI Pharma Award for Parkinson’s diagnostics and therapy
German biotechnology company MODAG GmbH has won the CPHI Pharma Award 2026 in the API Development and Innovation category, recognising its approach to combining diagnostics for Parkinson’s disease with the development of a potential disease-modifying treatment. Based in…
-
New trial aims to halt Parkinson’s disease before its onset
A new clinical trial led by researchers at Yale School of Medicine is investigating whether Parkinson’s disease can be slowed or prevented before motor symptoms appear. The PRISMS study is testing the anti-inflammatory drug adalimumab in people with REM sleep behaviour disorder…